- By insider

CEO of Emergent Biosolutions Inc (EBS) Daniel Abdun-nabi sold 90,776 shares of EBS on 09/05/2018 at an average price of $60.18 a share. The total sale was $5.5 million.

Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics. Emergent BioSolutions Inc has a market cap of $2.95 billion; its shares were traded at around $58.92 with a P/E ratio of 26.33 and P/S ratio of 4.34. Emergent BioSolutions Inc had annual average EBITDA growth of 11.30% over the past ten years.

• Warning! GuruFocus has detected 3 Warning Signs with EBS. Click here to check it out.

• EBS 15-Year Financial Data

• The intrinsic value of EBS

• Peter Lynch Chart of EBS

CEO Recent Trades:

• CEO Daniel Abdun-nabi sold 90,776 shares of EBS stock on 09/05/2018 at the average price of $60.18. The price of the stock has decreased by 2.09% since.

Directors and Officers Recent Trades:

• Director Ronald Richard sold 7,893 shares of EBS stock on 08/21/2018 at the average price of $60.02. The price of the stock has decreased by 1.83% since.

• Chairman, 10% Owner Fuad El-hibri sold 36,318 shares of EBS stock on 08/14/2018 at the average price of $55.98. The price of the stock has increased by 5.25% since.

For the complete insider trading history of EBS, click here

.This article first appeared on GuruFocus.

• Warning! GuruFocus has detected 3 Warning Signs with EBS. Click here to check it out.

• EBS 15-Year Financial Data

• The intrinsic value of EBS

• Peter Lynch Chart of EBS